Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer

Hari Singhal, Marianne E. Greene, Gerard Tarulli, Allison L. Zarnke, Ryan J. Bourgo, Muriel Laine, Ya Fang Chang, Shihong Ma, Anna G. Dembo, Ganesh V. Raj, Theresa E. Hickey, Wayne D. Tilley, Geoffrey L. Greene

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The functional role of progesterone receptor (PR) and its impact on estrogen signaling in breast cancer remain controversial. In primary ER(+) (estrogen receptor-positive)/PR(+) human tumors, we report that PR reprograms estrogen signaling as a genomic agonist and a phenotypic antagonist. In isolation, estrogen and progestin act as genomic agonists by regulating the expression of common target genes in similar directions, but at different levels. Similarly, in isolation, progestin is also a weak phenotypic agonist of estrogen action. However, in the presence of both hormones, progestin behaves as a phenotypic estrogen antagonist. PR remodels nucleosomes to noncompetitively redirect ER genomic binding to distal enhancers enriched for BRCA1 binding motifs and sites that link PR and ER/PR complexes. When both hormones are present, progestin modulates estrogen action, such that responsive transcriptomes, cellular processes, and ER/PR recruitment to genomic sites correlate with those observed with PR alone, but not ER alone. Despite this overall correlation, the transcriptome patterns modulated by dual treatment are sufficiently different from individual treatments, such that antagonism of oncogenic processes is both predicted and observed. Combination therapies using the selective PR modulator/antagonist (SPRM) CDB4124 in combination with tamoxifen elicited 70% cytotoxic tumor regression of T47D tumor xenografts, whereas individual therapies inhibited tumor growth without net regression. Our findings demonstrate that PR redirects ER chromatin binding to antagonize estrogen signaling and that SPRMs can potentiate responses to antiestrogens, suggesting that cotargeting of ER and PR in ER(+)/PR(+) breast cancers should be explored.

Original languageEnglish (US)
Pages (from-to)e1501924
JournalScience advances
Volume2
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Estrogens
Progestins
Transcriptome
Neoplasms
Hormones
Estrogen Antagonists
Estrogen Receptor Modulators
Nucleosomes
Tamoxifen
Heterografts
Chromatin
Binding Sites

Keywords

  • agonism
  • antagonism
  • BRCA1
  • breast cancer
  • chromatin
  • Estrogen
  • progesterone
  • prognosis
  • reprogramming
  • therapies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Singhal, H., Greene, M. E., Tarulli, G., Zarnke, A. L., Bourgo, R. J., Laine, M., ... Greene, G. L. (2016). Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Science advances, 2(6), e1501924. https://doi.org/10.1126/sciadv.1501924

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. / Singhal, Hari; Greene, Marianne E.; Tarulli, Gerard; Zarnke, Allison L.; Bourgo, Ryan J.; Laine, Muriel; Chang, Ya Fang; Ma, Shihong; Dembo, Anna G.; Raj, Ganesh V.; Hickey, Theresa E.; Tilley, Wayne D.; Greene, Geoffrey L.

In: Science advances, Vol. 2, No. 6, 01.06.2016, p. e1501924.

Research output: Contribution to journalArticle

Singhal, H, Greene, ME, Tarulli, G, Zarnke, AL, Bourgo, RJ, Laine, M, Chang, YF, Ma, S, Dembo, AG, Raj, GV, Hickey, TE, Tilley, WD & Greene, GL 2016, 'Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer', Science advances, vol. 2, no. 6, pp. e1501924. https://doi.org/10.1126/sciadv.1501924
Singhal, Hari ; Greene, Marianne E. ; Tarulli, Gerard ; Zarnke, Allison L. ; Bourgo, Ryan J. ; Laine, Muriel ; Chang, Ya Fang ; Ma, Shihong ; Dembo, Anna G. ; Raj, Ganesh V. ; Hickey, Theresa E. ; Tilley, Wayne D. ; Greene, Geoffrey L. / Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. In: Science advances. 2016 ; Vol. 2, No. 6. pp. e1501924.
@article{ae7f56701ad54520b15e167011a3c2eb,
title = "Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer",
abstract = "The functional role of progesterone receptor (PR) and its impact on estrogen signaling in breast cancer remain controversial. In primary ER(+) (estrogen receptor-positive)/PR(+) human tumors, we report that PR reprograms estrogen signaling as a genomic agonist and a phenotypic antagonist. In isolation, estrogen and progestin act as genomic agonists by regulating the expression of common target genes in similar directions, but at different levels. Similarly, in isolation, progestin is also a weak phenotypic agonist of estrogen action. However, in the presence of both hormones, progestin behaves as a phenotypic estrogen antagonist. PR remodels nucleosomes to noncompetitively redirect ER genomic binding to distal enhancers enriched for BRCA1 binding motifs and sites that link PR and ER/PR complexes. When both hormones are present, progestin modulates estrogen action, such that responsive transcriptomes, cellular processes, and ER/PR recruitment to genomic sites correlate with those observed with PR alone, but not ER alone. Despite this overall correlation, the transcriptome patterns modulated by dual treatment are sufficiently different from individual treatments, such that antagonism of oncogenic processes is both predicted and observed. Combination therapies using the selective PR modulator/antagonist (SPRM) CDB4124 in combination with tamoxifen elicited 70{\%} cytotoxic tumor regression of T47D tumor xenografts, whereas individual therapies inhibited tumor growth without net regression. Our findings demonstrate that PR redirects ER chromatin binding to antagonize estrogen signaling and that SPRMs can potentiate responses to antiestrogens, suggesting that cotargeting of ER and PR in ER(+)/PR(+) breast cancers should be explored.",
keywords = "agonism, antagonism, BRCA1, breast cancer, chromatin, Estrogen, progesterone, prognosis, reprogramming, therapies",
author = "Hari Singhal and Greene, {Marianne E.} and Gerard Tarulli and Zarnke, {Allison L.} and Bourgo, {Ryan J.} and Muriel Laine and Chang, {Ya Fang} and Shihong Ma and Dembo, {Anna G.} and Raj, {Ganesh V.} and Hickey, {Theresa E.} and Tilley, {Wayne D.} and Greene, {Geoffrey L.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1126/sciadv.1501924",
language = "English (US)",
volume = "2",
pages = "e1501924",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "6",

}

TY - JOUR

T1 - Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer

AU - Singhal, Hari

AU - Greene, Marianne E.

AU - Tarulli, Gerard

AU - Zarnke, Allison L.

AU - Bourgo, Ryan J.

AU - Laine, Muriel

AU - Chang, Ya Fang

AU - Ma, Shihong

AU - Dembo, Anna G.

AU - Raj, Ganesh V.

AU - Hickey, Theresa E.

AU - Tilley, Wayne D.

AU - Greene, Geoffrey L.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The functional role of progesterone receptor (PR) and its impact on estrogen signaling in breast cancer remain controversial. In primary ER(+) (estrogen receptor-positive)/PR(+) human tumors, we report that PR reprograms estrogen signaling as a genomic agonist and a phenotypic antagonist. In isolation, estrogen and progestin act as genomic agonists by regulating the expression of common target genes in similar directions, but at different levels. Similarly, in isolation, progestin is also a weak phenotypic agonist of estrogen action. However, in the presence of both hormones, progestin behaves as a phenotypic estrogen antagonist. PR remodels nucleosomes to noncompetitively redirect ER genomic binding to distal enhancers enriched for BRCA1 binding motifs and sites that link PR and ER/PR complexes. When both hormones are present, progestin modulates estrogen action, such that responsive transcriptomes, cellular processes, and ER/PR recruitment to genomic sites correlate with those observed with PR alone, but not ER alone. Despite this overall correlation, the transcriptome patterns modulated by dual treatment are sufficiently different from individual treatments, such that antagonism of oncogenic processes is both predicted and observed. Combination therapies using the selective PR modulator/antagonist (SPRM) CDB4124 in combination with tamoxifen elicited 70% cytotoxic tumor regression of T47D tumor xenografts, whereas individual therapies inhibited tumor growth without net regression. Our findings demonstrate that PR redirects ER chromatin binding to antagonize estrogen signaling and that SPRMs can potentiate responses to antiestrogens, suggesting that cotargeting of ER and PR in ER(+)/PR(+) breast cancers should be explored.

AB - The functional role of progesterone receptor (PR) and its impact on estrogen signaling in breast cancer remain controversial. In primary ER(+) (estrogen receptor-positive)/PR(+) human tumors, we report that PR reprograms estrogen signaling as a genomic agonist and a phenotypic antagonist. In isolation, estrogen and progestin act as genomic agonists by regulating the expression of common target genes in similar directions, but at different levels. Similarly, in isolation, progestin is also a weak phenotypic agonist of estrogen action. However, in the presence of both hormones, progestin behaves as a phenotypic estrogen antagonist. PR remodels nucleosomes to noncompetitively redirect ER genomic binding to distal enhancers enriched for BRCA1 binding motifs and sites that link PR and ER/PR complexes. When both hormones are present, progestin modulates estrogen action, such that responsive transcriptomes, cellular processes, and ER/PR recruitment to genomic sites correlate with those observed with PR alone, but not ER alone. Despite this overall correlation, the transcriptome patterns modulated by dual treatment are sufficiently different from individual treatments, such that antagonism of oncogenic processes is both predicted and observed. Combination therapies using the selective PR modulator/antagonist (SPRM) CDB4124 in combination with tamoxifen elicited 70% cytotoxic tumor regression of T47D tumor xenografts, whereas individual therapies inhibited tumor growth without net regression. Our findings demonstrate that PR redirects ER chromatin binding to antagonize estrogen signaling and that SPRMs can potentiate responses to antiestrogens, suggesting that cotargeting of ER and PR in ER(+)/PR(+) breast cancers should be explored.

KW - agonism

KW - antagonism

KW - BRCA1

KW - breast cancer

KW - chromatin

KW - Estrogen

KW - progesterone

KW - prognosis

KW - reprogramming

KW - therapies

UR - http://www.scopus.com/inward/record.url?scp=84997587752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997587752&partnerID=8YFLogxK

U2 - 10.1126/sciadv.1501924

DO - 10.1126/sciadv.1501924

M3 - Article

C2 - 27386569

AN - SCOPUS:84997587752

VL - 2

SP - e1501924

JO - Science advances

JF - Science advances

SN - 2375-2548

IS - 6

ER -